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Abstract
Background: In the general geriatric population, programs linking geriatric evaluation with interventions are
effective for improving functional status and survival of the patients. Whether or not these interventions improve
health related quality of life (HRQoL) or overall survival (OS) in older patients with cancer is not yet clear. Indeed,
randomized data on the effect of such interventions on survival and HRQoL are rare and conflicting. We describe
the rationale and design of a phase III multicenter trial aimed at assessing the efficacy of geriatric intervention in
the management of elderly patients with cancer.
Methods/design: Approximately 1200 patients, 70 years and older, considered in need of a geriatric intervention
based on the G8 screening tool will be randomized into two intervention arms. The ‘Usual-care’ arm involves
standard oncological care based on pre-defined oncological protocols. In addition to the standard oncological care,
the ‘Case-management’ arm involves a multidimensional geriatric assessment and interventions tailored for the
patient. Efficacy will be assessed using a co-primary endpoint encompassing OS and HRQoL.
Discussion: This trial has been designed to assess whether focused geriatric case management can either improve
OS or HRQoL in elderly cancer patients considered in need of geriatric assessment.
Trial registration: Clinicaltrials.gov ID: NCT02704832.
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Background
As the worldwide population ages and progress in cancer
treatment increases survival, improving the management
of older patients with cancer has become a major public
health issue. Significant progress has been made in recent
years, and geriatric assessment tools with prognostic value
to identify specific problems in the elderly cancer popula-
tion have been developed and validated [1–4]. However,
this approach takes time and skills to administer and
interpret, and only a few teams in France can perform full
geriatric assessment in routine practice for all elderly
cancer patients. We have developed [5] and validated the
G8 screening tool [3], a short, easy-to-administer screening
tool to identify patients in need of comprehensive geriatric
assessment (CGA) and specialized interventions. However,
the impact of further geriatric interventions on elderly
cancer patient outcomes has not yet been investigated.
A number of randomized trials on geriatric interven-
tions have shown benefit in various aspects for older
cancer patients such as physical activity levels or health
related quality of life (HRQoL) (Table 1). Goodwin et al.
reported that nurse case management had a positive im-
pact on the management of elderly patients with breast
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Table 1 Literature review of geriatric intervention programs
First author Study design N Population Mean age Intervention Primary end-point Results
Bourdel-
Marchasson [13]
Multicenter RCT* 336 Patients with solid tumor
treated by chemotherapy
at risk of malnutrition
(17 ≤MNA≤ 23.5).
78.0y 3–6 months diet
counselling intervention
1-year mortality - Early dietary counselling was efficient in increasing
intake but had no beneficial effect on mortality.
Hempenius [10] Multicenter RCT 260 Frail elderly patients
undergoing elective
surgery for a solid tumor
≈77.5y Geriatric liaison
intervention
Postoperative delirium - Intervention for frail elderly cancer patients
receiving surgery to prevent post-operative







survivors (≥5 years) of
colorectal, breast and
prostate cancer




Change in functional status
(baseline/12-month and 24-month)
Diet quality, BMI and physical activity
- Significant change in functional status between
intervention group and control group (p < 0.01):
amelioration of functional decline in intervention
group. Significant change in diet quality, physical
activity and BMI (p < 0.01).
Morey [7] Change in functional status
(baseline/12 m) using the
Medical Outcomes Study SF36
questionnaire, health-related QoL
- Significant change in physical function (p = 0.03)
and QoL (p = 0.007) between groups.




33 New advanced cancer
diagnosis (5-year OS:




QoL measured with Spitzer
uniscale and linear analogue
self-assessment (LASA) at baseline
and weeks 4, 8, and 27
- Significant improvement in QoL (p < 0.05) at baseline,
maintained at 4 and 8 weeks.
Rao [14] Subset analysis
from RCT [36]
99 Frail elderly cancer
patients hospitalized
on a medical or surgical
ward (≥2 days)
≈74y Geriatric assessment and
patient management by a
geriatric attending physician
and a social worker
12-month survival and health-
related QoL (after randomization),
ADL, physical performance, health
service utilization, and costs
- No significant effect on survival or QoL parameters.
Positive effects of geriatric inpatient care on mental
health and bodily pain (p < 0.05).
Days of hospitalization and cost similar.




≈72y 12-month nurse case
management
Type and use of cancer-specific
therapies received in the first
6 months after diagnosis.
Patient satisfaction and arm function
- More appropriate management for women receiving
nurse case management (Breast-conserving surgery,
adjuvant radiation, radiation therapy, axillary dissection
and breast reconstruction surgery).
Better arm function and higher satisfaction in
intervention group.




case management by nurse
Length of survival - Longer survival in intervention group than in usual
care group (p = 0.001).
Survival advantage for intervention group in
late stage patients.
Galvao [8] Two-arm single
center RCT
57 Prostate cancer patient
without bone metastases
treated by AST (≥2 months)
≈70y 12-week progressive
resistance and aerobic
training (2/week) by an
exercise physiologist
Muscle mass, strength, physical
function, QoL
- Significant change in total body lean mass, muscle
strength and endurance (p < 0.05). Change in QoL for
general health (p = 0.022), vitality (p = 0.019) and
physical health composite score (p = 0.02).











cancer [6]. Morey et al., in a 12-month home-based
study, reported the impact of physical activity in over-
weight, long-term cancer survivors older than 65 years
of age. They reported gains in function scores, basic
lower extremity function, dietary habits and an improve-
ment in the overall HRQoL [7]. In another study, an im-
provement in lean mass, muscle strength, walk time and
HRQoL was observed with a resistance and aerobic ex-
ercise program for 57 prostate cancer patients with a
mean age of 70 years [8]. Gains in practice of two or
more goal behaviors, exercise minutes per week, total fat,
saturated fat, and body mass index (BMI) were observed
for 443 patients with newly diagnosed loco-regional breast
or prostate cancer after a 10-month program of tailored
mailed print materials [9]. Geriatric intervention reduced
the pain in frail elderly patients who underwent elective
surgery for a solid tumor but did not have any significant
effect on delirium, complications, length of stay, care
dependency and HRQoL [10].
Geriatric intervention has also been shown to increase
overall survival (OS) in the general elderly population in
randomized controlled trials (RCTs) [11, 12]. However,
only few RCTs have investigated the impact specifically for
elderly cancer patients, with conflicting results. Bourdel-
Marchasson et al. [13] found no impact on 1-year mortality
after a nutritional intervention, and in a sub-analysis of a
larger trial, Rao et al. [14] found no difference in 1-year
survival after geriatric case-management for elderly cancer
patients. An improvement in survival was reported in an
RCT involving case-management in the form of a one-
month nurse intervention for post-surgical elderly cancer
patients, including 375 patients older than 60 years, but
this benefit was restricted to the sub-population of patients
with advanced disease [15].
Overall, results from various studies suggest that
geriatric interventions can potentially improve OS in
elderly cancer patients. Although several attempts are
being made to identify more patients at risk that re-
quire geriatric interventions, any OS or HRQoL bene-
fits following these interventions has not yet been
sufficiently demonstrated.
Our objective is to conduct a two-arm phase III trial to
assess the efficacy of geriatric intervention in the manage-
ment of elderly patients with cancer (targeted oncology
domains: breast, colorectal, lung, prostate, bladder, ovary,
lymphoma). The trial will be restricted to patients with an
abnormal G8 screening tool score that are considered in
need of a geriatric intervention. This trial protocol
was developed in collaboration with two national research
platforms (Cancer and Elderly Platform and Cancer
and Quality of Life Platform). We present here the key
elements of the trial: objectives, study design, target popu-





The primary objective of the trial is to compare the efficacy
of two treatment strategies “usual care” and “Case-manage-
ment intervention” in elderly cancer patients considered in
need of a geriatric assessment (G8 score ≤ 14). Treatment
strategies are defined as follows:
 “Usual care”: Patients are treated according to
ongoing standards in oncology.
 “Case-management intervention”: Patients are
treated according to ongoing standards in oncology
as in the “Usual care” arm. In addition, patients
receive geriatric assessments and interventions
coordinated by a geriatrician and a trained nurse,
and tailored for the patient.
The intervention content for each arm has been pre-
cisely defined by a panel of experts in geriatric oncology.
Efficacy will be assessed using a co-primary endpoint
encompassing OS and three targeted HRQoL dimensions
(global health status, physical functioning and emotional
functioning as measured using the European Organization
for Research and Treatment of Cancer, EORTC, QLQ-C
30 questionnaire [16]). Specifically, efficacy of the “Case-
management intervention” will be considered superior to
that of “Usual care” if, at one year, compared to usual care,
improvement is observed for OS or at least one of the tar-
geted HRQoL dimensions. We provide additional details
of the primary endpoint in evaluation criteria and sample
size calculation sections.
Secondary objectives
Secondary objectives are three-fold. First, in the popula-
tion of elderly cancer patients considered in need of a
geriatric assessment (G8 score ≤ 14), we will compare
the two treatment strategies in terms of additional end-
points: 6-month objective response, 1- and 3-year
progression-free-survival (PFS) and OS, HRQoL dimen-
sions other than those targeted for the primary endpoint,
grade 3–4 toxicities, duration and number of hospitali-
zations, place of residence (home versus nursing home
or hospital).
Second, we will focus on the population recruited in the
intervention arm. Our objective is to provide a description
of geriatric parameters (evolution over one year, as well as
descriptive data at baseline, 6 and 12 months): functional
status, nutritional status, depression status, physical
capacities, number and type of prescribed geriatric
interventions.
Third, while our main focus is on elderly cancer pa-
tients considered in need of a geriatric assessment
(G8 score ≤ 14), we also intend to provide a brief
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description of patients with a normal G8-score. Vital
status, place of residence and disease progression at
one year will be described.
Overall study design
The efficacy of the treatment strategies “Usual care” and
“Case-management intervention” will be assessed using
a two-arm randomized multicenter trial, conducted in
elderly cancer patients considered in need of a geriatric
assessment (G8 score ≤ 14).
As additional objectives involve describing elderly can-
cer patients with a normal G8-score, a specific cohort
will be built in parallel to the randomized trial. Patients
initially screened for inclusion in the randomized trial
but who will present with a G8 score ≤ 14 will be in-
cluded in this parallel prospective cohort.
All elderly cancer patients treated at participating
centers will first be screened with the G8 instrument
(Appendix A). If the G8 score is altered (G8 score ≤ 14)
then patients will be included in the main trial and ran-
domized between “Usual care” and “Case-management
intervention” (Fig. 1). For each arm, patients will be
treated according to protocols specifically defined for this
trial (See section “Description of the interventions”). If the
resulting score is normal (G8 > 14) then patients will be
included in the parallel cohort and treated according to
the institution’s standard management process.
This study will be initially proposed to the 28 Regional
Coordination Units for Geriatric Oncology accredited
to the French National Cancer Institute across France,
including Comprehensive Cancer Centers, teaching hospi-
tals, public hospitals and private practices.
Data will be collected on an electronic case report
form and directly input via the Internet. Data will be han-
dled by online trial management software on the Internet;
it will be transferred and monitored remotely in real-time.
Similarly, randomization will proceed through internet-
based software allowing rapid randomization at any time.
Eligibility criteria
This study will include patients 70 years and older. In
addition, patients must meet the following criteria:
performance status 0 to 3 (WHO), candidate to 1st line
medical treatment (excluding best supportive care) of
breast, colon, rectal, lung, prostate, bladder, or ovarian
cancer and lymphomas (indolent and aggressive); exclud-
ing exclusive hormonotherapy (except prostate cancer); or,
second line medical treatment (excluding Best Supportive
Care) of breast, colon, rectal, prostate cancer, ovary and
indolent lymphoma.
Exclusion criteria are life expectancy under 6 months,
presence of any psychological, familial, sociological or
geographical condition potentially hampering compli-
ance with the study protocol and follow-up schedule,
participation at the same time in another study in which
investigational drugs are used, and patients who have
already received two lines of treatment or for whom hor-
monal treatment (except for abiraterone acetate and
enzalutamide in prostate cancer) or best supportive care
is indicated.
Description of the interventions
All patients included in the randomized trial will receive
cancer care according to ongoing standards in oncology.
The content of this intervention has been precisely de-
fined in a cancer care protocol by a panel of experts in
geriatric oncology, and depending on the disease and
stage. For patients specifically randomized in the “Case-
management intervention”, intervention will, in addition,
involve multidimensional geriatric assessments and case-
management geriatric interventions tailored for the pa-
tient. Similarly, this specific geriatric intervention has
been precisely defined in a geriatric care protocol by a
panel of experts in geriatric oncology. We first describe
the development process for the cancer care protocol
and the geriatric care protocol followed by details of the
content of each protocol.
Development of the standard cancer care and geriatric
intervention plans
The objective of this preliminary phase is to propose
protocols for both cancer care and geriatric care for
patients included in the randomized trial in order to en-
sure homogeneous oncological care (across treatment
arms and between investigational sites) as well as homo-
geneous interventions in geriatrics (within the arm
“Case-management intervention” and between investiga-
tional sites). Firstly, although the trial is aimed at assessing
the efficacy of the geriatric intervention, it is important to
acknowledge that for same disease, several cancer treat-
ment options can be proposed, and dose adjustments are
expected. By providing a cancer care protocol, clinicians
will have a specific list of cancer treatment options for
which they will be able to select an option. Secondly, it is
important to ensure that patients who will be randomized
in the geriatric intervention arm will be followed-up and
treated according to a standardized procedures (use of the
same questionnaires, same decision rules to propose spe-
cific interventions, etc.), justifying the development of a
geriatric care protocol.
To develop and validate the final version of both the
cancer care and the geriatric care protocols, two inde-
pendent committees were set up for each protocol: a
writing committee and a peer-review committee. For
the cancer care protocol, the writing committee led by
an oncologist (CT) consisted of seven additional ex-
perts in each targeted oncology domain (breast, colo-
rectal, lung, prostate, bladder, lymphoma, or ovarian
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cancer), and the validation committee included four on-
cologists and one geriatrician. For the geriatric care
protocol, the writing committee consisted of two geria-
tricians (MR and OSJ) and one nurse qualified in geri-
atric oncology (MDZ), and the validation committee
included one oncologist and four geriatricians. The
complete list of experts constituting the committees is
provided in Appendix B.
Once the protocols were drafted by the writing com-
mittee, they were sent to the peer-review committee for
assessment and comments with a standardized ques-
tionnaire consisting of seven questions on the clarity,
appropriateness and applicability of the proposed pro-
tocols. Members provided a formal and advisory opin-
ion on content and form of the initial version of the
guidelines. Minor modifications to the protocols were
incorporated following the review. Final documents
were then redistributed to the writing committees for
validation. This review process was an essential quality
assurance step and the final document was circulated
to all participating investigators of the trial and will
serve as a reference document.
Description of the intervention for the arm ‘Usual care’
Patients will be treated according to the cancer care
protocol, which provides, for each cancer site, a list of
treatment options as well as guidelines for dose modifi-
cations and adverse event management. The complete
cancer care protocol is available upon request.
Patients will be followed-up by the oncologist for three
years after randomization. Baseline assessment includes
clinical examination, laboratory tests (hematology, bio-
chemistry and/or creatinine clearance), disease history
and treatments, tumor assessment, and HRQoL assess-
ment (QLQ-C30 and ELD-14). Quarterly visits by the
oncologist during the first year will include a clinical
examination, laboratory tests, tumor assessment, and
HRQoL assessment (QLQ-C30 and ELD-14 question-
naires). Patients will then be seen every semester during
the second and third years during which data on disease
progression, HRQoL and vital status will be collected.
Description of the intervention for the arm “Case-management
intervention”
Patients will be treated according to the oncological
standards, as defined in the cancer care protocol. Pa-
tients’ follow-up with their oncologist will be identical to
that of patients in the ‘Usual care’ arm. In addition,
intervention will also involve case-management geriatric
interventions tailored for the patient. The geriatric
care protocol provides a full description of the case-
management process which includes CGAs, telephone
follow-ups by the nurse and patient file reviews by the
geriatrician and the nurse.
The patient will be seen by the geriatrician and the
nurse for CGA at baseline (after randomization and be-
fore treatment initiation), as well as 6 and 12 months
after randomization. The CGA will include the follow-
ing: questionnaires completed with the nurse (Activities
of Daily Living (ADL) [17], Instrumental ADL (IADL),
Mini Mental State Examination (MMSE) [18], Mini Nu-
tritional Assessment (MNA) [19], Geriatric Depression
Scale (GDS-15) [20], EORTC QLQ-C 30 [16] and the
Elderly Cancer Patients version (EORTC QLQ- ELD14)
[21]); social evaluation including mode of living, profes-
sional help, social situation; geriatric clinical consultation
including Timed Up and Go (TUG) [22], Short Perform-
ance Physical battery (SPPB [23]), weight loss, subjective
health, falls in last 12 months, co-morbidities, other
medical treatment, pain (numerical scale) and sleep pat-
terns; geriatric patient management plan defined by
nurse and geriatrician. The geriatric management plan
establishing any necessary interventions will be defined
by the nurse and the geriatrician across eleven interven-
tion areas according to the predefined rules in the
geriatric care protocol. Table 2 presents a summary of
these interventions for the eleven intervention areas:
modification of therapy, balancing chronic diseases,
pain treatment, nutritional intervention, physical ac-
tivity, physiotherapy, psychological support, prevention
of further cognitive impairment, treatment of sleeping
disorders, assistance, and home help. For illustration,
with regards to nutritional intervention, weight loss
over the last three and six months should be assessed
and the MNA questionnaire should be completed.
The patient will be considered at risk of malnutrition
in case of MNA score between 17 and 23.5 and in such
case, advice on increasing dietary uptake (use of food
pyramid adapted for elderly patients) should be provided
as presented in the geriatric protocol. On the other hand,
in case of an MNA score below 17, weight loss greater
than 5% over the last three months or 10% over the last
six months, then the patient will be considered malnour-
ished, and should be referred to a dietician.
Telephone follow-ups by the nurse will take place on a
monthly basis for the first semester, then every three
months up to one year, or after any event, such as
hospitalization, or change of residence to nursing home.
The following information should be recorded: clinical sta-
tus of the patient including factors assessed at the 1-month
review, any toxicity to treatment, social assistance in place,
and coordination of future consultations.
Patient file reviews will take place after telephone
follow-ups and will involve the geriatrician, the nurse
and the oncologist in order to review how the geriatric
interventions in place are progressing, and assess the
need for further interventions according to the prede-
fined rules (Table 2).
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To standardize care in the “Case-Management arm”, a
two-day training for nurses will be organized. Two
nurses per investigating center will participate in the
training which will be mandatory before the center can
accrue. During this training session, nurses will be trained
to perform the telephone follow-ups with patients.
Description of the intervention for patients included in the
parallel cohort
Patients with a normal G8 score will be included in the
parallel cohort and treated according to the institution’s
standard management process.
Evaluation criteria
Although OS is a usual endpoint to assess treatment
efficacy in RCTs, it may not be sufficient to assess the treat-
ment benefit in an elderly population. The effect on
HRQoL should also be considered, since it may be as im-
portant as (and sometimes more than) duration of life for
this population [24, 25]. Efficacy will be assessed using a
co-primary endpoint encompassing OS and three targeted
HRQoL dimensions including global health status, physical
functioning and emotional functioning as measured using
the EORTC QLQ-C 30 questionnaire [16]. Specifically, effi-
cacy of the “case-management intervention” will be consid-
ered superior to that of “usual care” at one year, if there is
a significant clinical improvement in OS without a signifi-
cant deterioration in at least one of the targeted HRQoL
dimensions, or if there is a significant clinical improve-
ment in at least one of the targeted HRQoL dimension
without a significant difference in OS.
OS is defined as the delay between the date of
randomization and the date of death. If the absolute
difference in OS at one year is at least 10% greater,
then we will consider it as a significant improvement
in the OS. For HRQoL, the three targeted dimensions will
be assessed using the EORTC QLQ-C 30 questionnaire
[16]. Dimensions will be scored according to the EORTC
Table 2 Proposed geriatric interventions defined in protocol according to the eleven areas and screening tools used
Area Indication Intervention
Modification of therapy Polypharmacy • Re-evaluate treatment indications (with general practitioner),
optimize treatment according to elderly patient protocols.
• Use the STOPP-START* tool as a reference [37, 38].
Balancing chronic diseases CIRS-G* Grade≥ 3, • Adaptation of therapy.
arterial hypertension, diabetes, arthritis, or sensory problems • Other non-drug interventions such as dietary advice, devices.
• Referral to specialist doctor.
Pain treatment Pain >1 on numeric scale • Drug: WHO levels 1–3 antalgic treatment
• Non-drug: physiotherapy, devices
Nutritional intervention Malnutrition (MNA*≤ 17) • Referral to dietician (nutritional supplements, artificial nutrition, etc.)
Weight loss ≥5 % over 3 m, or ≥10 % over 6 m
At risk of malnutrition - 17 <MNA≤ 23.5 • Advice on increasing dietary uptake (use of food pyramid
adapted for elderly patients)
Physical activity Sedentary or at risk of falls • Recommend daily walk, walking upstairs, carrying groceries
Physiotherapy Difficulty with walking and balance (TUG*, and SPPB*).
Fall in the last 12 m, weight loss, muscle loss
• Prescribe physiotherapy for muscular reinforcement Work on
balance, and getting up from lying down position
• Prescribe walking aids
Psychological support GDS*≥ 6 • Consultation with psychologist or psychiatrist




MMSE* < 24 • Behavioral monitoring during chemotherapy
• Prevention of confusion [39]
Treatment for
sleeping disorders
Positive screening score on adapted Epworth scale [40] • Introduction, modification or discontinuation of treatment by
hypnosis according to STOPP and START recommendations [37, 38]
Assistance Social fragility identified (absence of social support) • Ask patient directly if help is needed
• Refer to a social worker
Home help Difficulties performing daily tasks such as grooming,
housework
• Prescribe support within the home (nursing, physiotherapy,
housecleaner, etc.)
*STOPP-START Screening Tool of Older persons’ prescriptions, CIRS-G Cumulative Illness Rating Scale for Geriatrics, MNA Mini Nutritional Assessment, TUG Timed Up
and Go, SPPB Short Performance Physical battery, GDS Geriatric Depression Scale, MMSE Mini mental state examination
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manual [26]. Each dimension will be scored ranging
from 0 to 100 and a difference of 10 points or greater
will be considered to be clinically significant [27]. If there
is a major improvement in at least one of the three scales,
without deterioration of the other two, then we will con-
sider as a significant improvement in HRQoL. Secondary
endpoints include PFS defined as the delay between the
date of randomization and the date of progression or
death whichever occurs first. Progression, as well as object-
ive response, will be defined as per the RECIST criteria for
solid tumors [28] or the Cheson criteria for lymphomas
[29]. HRQoL dimensions other than those targeted for the
primary efficacy endpoints will similarly be assessed based
on the EORTC scoring manual, and the EORTC ELD-14
module will be assessed following published guidelines
[30]. For each of the HRQoL dimensions, time until defini-
tive deterioration (TUDD) will be investigated and defined
based on a recent publication [31]. Toxicities will be
graded according to the NCI-CTC v4.3 classification. For
geriatric questionnaires (G8, ADL, IADL, MNA, MMSE,
GDS-15, CIRS-G, TUG), cut-off scores used to define
abnormal scores are those reported in the corresponding
literature and summarized in Soubeyran et al. [3].
Statistical methods
Randomization
For the phase III trial, randomization will be performed
on an individual basis based on a 1:1 allocation ratio.
Randomization will be stratified by investigational site,
treatment line (first or second), and type of cancer (breast,
colon, rectal or prostate cancer versus bladder, ovarian, or
lung cancer or lymphoma). Because of the number of
strata foreseen, randomization by minimization will be
implemented [32].
Sample size
Sample size was estimated for the randomized trial. For
the null hypothesis we assumed no difference in OS and
no difference in the three targeted HRQoL dimensions
between the two intervention arms. Alternative hypoth-
eses were two-fold: improvement in OS or improvement
in HRQoL. The 5% two-sided type-1 error rate was
therefore split between the two alternative hypotheses
with 2% for OS and 1% for each of the three HRQoL
dimensions. Sample size improvement for testing im-
provement in OS assumed the following hypotheses:
2% (two-sided) type-1 error rate, 85% power, antici-
pated 1-year 50% OS rate in the ‘usual care’ group [13],
60% expected 1-year 60% OS rate in the “Case-manage-
ment” arm (ie anticipated hazard ratio, HR = 0.74).
These hypotheses led to an estimated sample size of
1096 subjects (548 per group; 486 events) needed to
detect a difference in OS (log-rank test). Sample size
for testing improvement in HRQoL was based on a 3%
(two-sided) type-1 error. If the intervention is effective,
we expect that it will allow us to detect, at one year, a
mean difference of 10 points or more for at least one of
the three targeted HRQoL scores (common standard
deviation of 20 points). Each of the three scales will be
independently tested. Five hundred and forty eight sub-
jects per group (as needed for OS comparison) will
provide sufficient power (>90%) for independently test-
ing the three HRQoL scales at 1% (2-group t-tests of
equal means – common variance).
To anticipate for non-assessable subjects (10%), 1200
patients need to be randomized (ie with G8 score ≤ 14).
Based on previous research [5] about 80% of the patients
are expected to have positive G8, thus 1500 patients need
to be screened for inclusion in the randomized trial.
Since 20% are expected to have normal G8 score, about
300 patients will be included in the parallel cohort.
Following our previous experience with the ONCODAGE
validation study [3] which included 1668 patients over
18 months, we expect that 800 patients will be screened
each year, leading to an expected inclusion period of 1.5 to
2 years. To reach all endpoints, three years of follow-up
are required, giving total study duration of 5 years.
Statistical analyses
For the randomized trial, different analysis sets will be
defined including the intent-to-treat (ITT) population
(all randomized patients included and analyzed according
to the allocated intervention), modified ITT population
(mITT: all randomized patients with baseline HRQoL in-
cluded and analyzed according to the allocated interven-
tion) and per protocol population (PP: eligible patients
and analyzed according to the intervention actually re-
ceived). These three populations will be described accord-
ing to the following characteristics: compliance with
eligibility criteria, epidemiological characteristics, clinical
and laboratory characteristics, treatment characteristics,
and HRQoL. For the co-primary endpoints, the primary
analysis will be conducted in the mITT population,
with sensitivity analyses conducted in the PP popula-
tion. OS will first be compared based on a log-rant
test stratified on randomization factors (2% type 1 error
rate). Additional analyses will be conducted including Cox
regression modeling to provide an estimate of the effect
size of the intervention, after checking for underlying
model assumptions. For each targeted HRQoL dimension,
a t-test assuming common variances will be conducted
(1% type 1 error rate). Sensitivity analyses assuming a
mean difference of 5 points or more for at least one of the
targeted HRQoL scores will be conducted. In addition,
variance analysis will be conducted for adjustment on
randomization factors and additional covariates. Other
endpoints will be analyzed using standard statistical tech-
niques. PFS will be analyzed using the same methods as
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for OS. Censoring mechanisms for the analysis of TUDD
will follow recommendations from Bonnetain et al. [28].
With regards to HRQoL data, missing data analysis will be
performed to determine the missing data profile. Longitu-
dinal models will be fitted to provide a description of the
HRQoL over time and investigate effect of the interven-
tion. For patients treated in the “Case-Management” arm,
the analysis of geriatric parameters will involve summary
statistics presented at various time-points as well longitu-
dinal analysis to investigate trends over time.
Monitoring and ethical considerations
The trial has been approved by the regional ethics com-
mittee (Comité de Protection des Personnes Sud-Ouest et
Outre Mer III) and by the National Agency for Security of
Medical and Health products (ANSM) and has been
registered (Trial registration number: 2015-A01417-42).
All patients will provide informed consent (both for the
randomized trial and prospective cohort) and will be free
to withdraw their consent at any time.
The study will be supervised and monitored continu-
ously by a steering committee consisting of the principal
investigator (oncologist), a coordinating geriatrician, a
pharmacist in charge of the pharmacovigilance, a bio-
statistician, a data manager and the coordinating clinical
research assistant. This committee will ensure the imple-
mentation and regular follow-up of the study, patient
protection, ethical conduct of trial and evaluation of
benefit/risk ratio. The scientific committee will include
the steering committee as well as additional geriatrics,
medical oncology, public health and biostatistics special-
ists. It will be responsible for validation modifications of
the study protocol and reviewing scientific findings dur-
ing the course of the study, providing patient protection,
ethical conduct of trial and evaluation of benefit/risk ra-
tio. An independent data monitoring committee (IDMC)
has been foreseen and will be set up at least once during
the course of the study.
Discussion
Currently, the G8 is recommended for systematic use in
France [33] to identify patients requiring increased clin-
ical attention up to full geriatric assessment, and poten-
tially a geriatric intervention plan. This generates a
certain cost, for the CGA and for the geriatric interven-
tions proposed, yet the gains in survival or HRQoL of
these geriatric interventions have not yet been demon-
strated. The current evidence to suggest that geriatric in-
terventions have a positive impact on survival and
HRQoL in elderly cancer patients is limited and conflict-
ing, and randomized controlled trial data in this specific
context are required.
The current study protocol proposes a two-arm ran-
domized comparison trial of usual cancer care versus
usual cancer care combined with geriatric intervention,
in a group of elderly patients across multiple centers in
France. Our randomized trial offers an innovative ap-
proach introducing a co-primary endpoint including
both OS and HRQoL. This methodology integrates the
HRQoL dimension in addition to life span, which may
reflect elderly people expectations.
As such, we propose to compare efficacy using a
co-primary endpoint encompassing OS and specific dimen-
sions of HRQoL at one year – this is the first time this
elderly-specific endpoint has been proposed in this context.
Appendix
Appendix A
Table 3 The G8 screening test
Items Possible answers (score)
A Has food intake declined over
the past 3 months due to loss
of appetite, digestive problems,
chewing or swallowing difficulties?
0 : severe decrease in
food intake
1 : moderate decrease
in food intake
2 : no decrease in
food intake
B Weight loss during the last 3 months 0 : weight loss > 3 kg
1 : does not know
2 : weight loss between
1 and 3 kgs
3 : no weight loss
C Mobility 0 : bed or chair bound
1 : able to get out of bed/
chair but does not go out
2 : goes out
E Neuropsychological problems 0 : severe dementia or
depression
1 : mild dementia or
depression
2 : no psychological problems
F Body Mass Index (BMI
(weight in kg)/(height in m2)
0 : BMI < 19
1 : BMI = 19 to BMI < 21
2 : BMI = 21 to BMI < 23
3 : BMI = 23 and > 23




P In comparison with other people of
the same age, how does the patient
consider his/her health status?
0 : not as good
0.5 : does not know
1 : as good
2 : better
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Appendix B: Writing and Validation Committees of the
Cancer Care Protocol
Writing Committee: Catherine Terret (Medical Oncologist,
Lyon, Chair), Thomas Aparicio (Gastro-enterologist, Paris),
Etienne Brain (Medical Oncologist, Paris), Camille Chakiba
(Medical Oncologist, Bordeaux), Stéphane Culine (Medical
Oncologist, Paris), Gilles Freyer (Medical Oncologist, Lyon),
Caroline Lalet (Central Clinical Research Assistant,
Bordeaux), Hervé Le Caer (Pneumologist, Draguignan),
Loic Mourey (Medical Oncologist, Toulouse), Pierre
Soubeyran (Medical Oncologist, Bordeaux).
Validation Committee: Leila BENGRINE-LEFEVRE
(Medical Oncologist, Dijon), Emmanuelle BOURBOULOUX
(Medical Oncologist, Nantes), Nicole TUBIANA-MATHIEU
(Medical Oncologist, Limoges), Simon VALERO (Geriatri-
cian, Poitiers).
Appendix C: Writing and Validation Committees of the
Geriatric Care Protocol
Writing Committee: Muriel Rainfray (Geriatrician, Bor-
deaux, Co-Chair), Olivier St Jean (Geriatrician, Paris, Co-
Chair), Camille Chakiba (Medical Oncologist, Bordeaux),
Caroline Lalet (Central Clinical Research Assistant,
Bordeaux), Marie-Dominique Zwolakowski (Advanced
Practice Nurse, Bordeaux).
Validation Committee: Laurent Balardy (Geriatrician,
Toulouse), Laurence CRISTOL-DALSTEIN (Geriatrician,
Montpellier), Jean-Yves NIEMIER (Geriatrician, Nancy),
Frédérique Retornaz (Geriatrician, Marseille), Véronique
SERVENT (Medical Oncologist, Lille).
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